New product: Tavlesse (fostamatinib)

This spleen tyrosine kinase inhibitor is licensed for the treatment of chronic immune thrombocytopenia in adults who are refractory to other treatments. The recommended starting dose is 100mg twice daily; dose adjustments are based on platelet count response and tolerability.

electronic Medicines compendium